electroCore (NASDAQ:ECOR) Price Target Raised to $25.00

electroCore (NASDAQ:ECOR) had its price objective raised by HC Wainwright from $22.00 to $25.00 in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for electroCore’s Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.60) EPS, FY2026 earnings at $0.52 EPS, FY2027 earnings at $1.34 EPS and FY2028 earnings at $2.24 EPS.

electroCore Stock Performance

Shares of ECOR opened at $15.27 on Wednesday. The business’s fifty day moving average price is $11.51 and its two-hundred day moving average price is $8.12. The firm has a market capitalization of $100.09 million, a price-to-earnings ratio of -8.34 and a beta of 0.57. electroCore has a 52 week low of $5.25 and a 52 week high of $17.84.

Institutional Trading of electroCore

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. HighTower Advisors LLC bought a new position in shares of electroCore in the 3rd quarter valued at about $255,000. International Assets Investment Management LLC boosted its stake in electroCore by 27.9% in the second quarter. International Assets Investment Management LLC now owns 67,820 shares of the company’s stock valued at $436,000 after acquiring an additional 14,800 shares during the last quarter. Renaissance Technologies LLC grew its holdings in electroCore by 3.4% during the 2nd quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock worth $442,000 after acquiring an additional 2,270 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of electroCore by 10.3% during the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock valued at $458,000 after acquiring an additional 5,951 shares during the last quarter. 26.74% of the stock is currently owned by institutional investors and hedge funds.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.